… 担任 《Lung Cancer》副主编,《Tanslational Lung Cancer Research》杂志主 编及《中国肺癌杂志
》,《… Crizotinib versus chemotherapy in advanced ALKpositive lung cancer[J]. N Engl J Med, …

… Crizotinib is superior to standard chemotherapy in patients with previously treated,
advanced ALK positive non-small cell lung cancer.The median PFS of patients is shorter.It can …

… 剂,对ALK 阳性的非小 细胞肺癌(non⁃small cell lung cancer,NSCLC)有显 著的抗肿瘤作用.PROFOLE
1014Ⅲ期研究已证 实,克唑替尼可以作为晚期ALK 阳性NSCLC 的一 线标准治疗方案. …

… Conclusions: This Meta analysis confirms the efficacy and safety of crizotinib. Crizotinib is
obviously superior to chemotherapy in the treatment of ALK positive NSCLC. The standard is …

… ALK-positive NSCLC patients demonstrated durable responses and well tolerance in the
majority of ALK-positive NSCLC patients treated with crizotinib. … resistance to crizotinib. Several …

… First-line crizotinib therapy combined with local brain treatment can improve intracranial
PFS for ALK-positive NSCLC with brain metastases.This finding should be confirmed further …

… gene of non⁃small⁃cell lung cancer(NSCLC),and ALK⁃… crizotinib in clinical practice.
Methods We retrospectively collected a total of 234 patients with ALK⁃positive advanced NSCLC …

… kinase (ALK) positive lung adenocarcinoma, but the efficacy in lung cancer with bone marrow
… case of ALK-positive lung adenocarcinoma with bone marrow matastasis given crizotinib …

… cell lung cancer (NSCLC). Several studies have shown that the efficacy of pemetrexed in
ALK-positive lung cancer is … -based chemotherapy in patients with ALK-positive and negative …

… advanced or recurrent NSCLC harboring ALK gene fusion/translocation. The patients with
ALK positive tested by flourescence in situ hybridization (FISH) was given orally crizotinib, 250 …